Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | GABRR1 | P24046 | 4/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23469096 | 0.84 | NOS3 (0.31) | EPHX2 | |
| SCHEMBL12077578 | 0.82 | TRPA1 (0.33) | EPHX2GABRR1L3MBTL1GABRR2 | |
| SCHEMBL3537569 | 0.82 | EPHX2 (0.33) | EPHX2HTR2AHTR2CHTR2BGABRR1 | |
| SCHEMBL3148808 | 0.81 | — | — | |
| SCHEMBL16191202 | 0.79 | L3MBTL1 (0.32) | L3MBTL1 | |
| SCHEMBL19934934 | 0.79 | — | — | |
| SCHEMBL6306091 | 0.79 | L3MBTL1 (0.32) | L3MBTL1 | |
| SCHEMBL10605419 | 0.78 | — | — | |
| SCHEMBL29201860 | 0.78 | EPHX2 (0.35) | EPHX2 | |
| SCHEMBL15107928 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046697-B2 | Compounds and compositions useful for treating disorders related to NTRK | BLUEPRINT MEDICINES CORPORATION | 2021-06-29 | — | — | US | disclosed |
| EP-2593077-B1 | CYCLOHEXYL CARBAMATE COMPOUNDS AS SKIN AND/OR HAIR LIGHTENING ACTIVES | SYMRISE AG (DE) | 2016-11-02 | — | — | EP | disclosed |
| US-9072676-B2 | Cyclohexyl carbamate compounds as skin and/or hair lightening actives | SYMRISE AG (DE) | 2015-07-07 | — | — | US | disclosed |
| US-9072676-B2 | Cyclohexyl carbamate compounds as skin and/or hair lightening actives | SYMRISE AG (DE) | 2015-07-07 | — | — | US | disclosed |
| US-9060949-B2 | Menthyl carbamate compounds as skin and/or hair lightening actives | SYMRISE AG (DE) | 2015-06-23 | — | — | US | disclosed |
| US-9060949-B2 | Menthyl carbamate compounds as skin and/or hair lightening actives | SYMRISE AG (DE) | 2015-06-23 | — | — | US | disclosed |
| US-9012497-B2 | Cyclohexyl carbamate compounds as active anti-cellulite ingredients | SYMRISE AG (DE) | 2015-04-21 | — | — | US | disclosed |
| US-9012497-B2 | Cyclohexyl carbamate compounds as active anti-cellulite ingredients | SYMRISE AG (DE) | 2015-04-21 | — | — | US | disclosed |
| US-20130156710-A1 | CYCLOHEXYL CARBAMATE COMPOUNDS AS SKIN AND/OR HAIR LIGHTENING ACTIVES | SYMRISE AG (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130156710-A1 | CYCLOHEXYL CARBAMATE COMPOUNDS AS SKIN AND/OR HAIR LIGHTENING ACTIVES | SYMRISE AG (DE) | 2013-06-20 | — | — | US | disclosed |
| EP-2389922-A1 | Cyclohexyl carbamate compounds as anti-ageing actives | Symrise AG (DE) | 2011-11-30 | — | — | EP | disclosed |
| US-7687507-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20050171128-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC | 2005-08-04 | — | — | US | disclosed |
| US-6890929-B2 | Immunosuppressants; lupus, multiple sclerosis, skin disorders, antiarthritic agents, antihistamines, antiulcer agents, Crohn's disease | PFIZER, INC. (US) | 2005-05-10 | — | — | US | disclosed |
| EP-1087970-B1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PROD INC (US) | 2004-04-28 | — | — | EP | disclosed |
| US-20030212273-A1 | Pyrrolo [2,3-D] pyrimidine compounds | PFIZER INC. | 2003-11-13 | — | — | US | disclosed |
| US-6610847-B2 | Tyrosine kinase inhibitors; immunosuppressants | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2002-02-14 | — | — | US | disclosed |
| EP-1087970-A1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065908-A1 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, JAK3, JAK2 | EPHX2 3013/4885HTR2A 4306/4885HTR2C 3868/4885 |
| US-20130156710-A1 | CYCLOHEXYL CARBAMATE COMPOUNDS AS SKIN AND/OR HAIR LIGHTENING ACTIVES | CBR1, CYP2A13, CBR3 | EPHX2 1593/4885HTR2A 653/4885HTR2C 493/4885 |
| US-20050171128-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK3, JAK1, JAK2 | EPHX2 3229/4885HTR2A 4287/4885HTR2C 3883/4885 |
| US-11046697-B2 | Compounds and compositions useful for treating disorders related to NTRK | NTRK3, NTRK2, NTRK1 | EPHX2 4375/4885HTR2A 2952/4885HTR2C 3084/4885 |
| US-20030212273-A1 | Pyrrolo [2,3-D] pyrimidine compounds | JAK1, JAK3, JAK2 | EPHX2 3013/4885HTR2A 4306/4885HTR2C 3868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.